Vertaling van "where a medicine needs " (Nederlands → Frans) :

This stands in stark contrast to for instance, oncology patients, where a medicine needs primarily to be effective.
This stands in stark contrast to for instance, oncology patients, where a medicine needs primarily to be effective.

Results of a one-year study, which was undertaken in response to “approvable letters” from the FDA, achieved primary efficacy and renal function targets and were also consistent with experience seen in 70 countries – including in Europe – where this medicine has been approved.
Les résultats d’une étude d’un an, entreprise en réponse à des «approvable letters» émises par la FDA, a atteints ses objectifs principaux en termes d’efficacité et de fonction rénale. Ces résultats étaient également en adéquation avec les expériences récoltées dans 70 pays – notamment en Europe – où ce médicament est autorisé.

Medicines discovered by the institute will be made available at cost to poor patients in those countries where they are most needed.
Les médicaments mis au point par l’Institut seront fournis à prix coûtant aux malades pauvres des pays où les besoins sont les plus urgents.

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the
However, if a medicine is being administered for which there is no MA, a minimum number of quality standards need to be put in place and a minimum guarantee needs to be provided through the animal tests conducted or existing experience with humans, suggesting that the

Diovan also maintained strong growth in Europe, where the expected entry of generic versions of losartan, another medicine in the angiotensin receptor blockers (ARB) segment, has been delayed until the first half of 2010.
Diovan a également conservé une forte croissance en Europe, où l’entrée attendue de versions génériques de losartan, un autre médicament faisant partie du segment des antagonistes des récepteurs de l’angiotensine (ARA), a été repoussée au premier semestre 2010.

The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.
The development of a medicine is a continuous process where the finetuning of the chemical–pharmaceutical process and the preclinical and clinical tests both occur in parallel and influence each other.

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.

There is still a significant need for developing better medicines in a number of domains.
There is still a significant need for developing better medicines in a number of domains.

Each new homeopathic medicine which has not already been notified needs to be authorised/registered before it can be marketed.
Each new homeopathic medicine which has not already been notified needs to be authorised/registered before it can be marketed.